Milnubes / Curiosity, with sourcesBotany · Culture · Science
milnubes.
Milnubes/Encyclopedia/CBL
Cannabinoid atlas / Reference entry
CBL
Plant cannabinoids

Cannabicyclol

A scientific profile needs to revisit its sources rather than simply repeat old conclusions. For CBL, the useful question is what each experiment supports and where interpretation begins. Keeping that boundary visible makes reading both more interesting and more precise.

Documentary review: Milnubes editorial desk · assisted by AI
Pale dried leaves on a white surface.
Stock dried leaves, not identified as cannabis: visual context for change, not a CBL sample.
Evidence map

Laboratory or animals. This label summarises the type of data; it is neither a recommendation to use nor a safety rating.

How we read studies and personal accounts ↗

Identity

Cannabicyclol: a cannabinoid containing a cyclobutane ring.

Source · Total Syntheses of Cannabicyclol, Clusiacyclol A and B, Iso-Eriobrucinol A and B, and Eriobrucinol

Terms associated with this entry: cannabicyclol.

Chemistry before promises

A 2013 synthesis paper included CBL: chemical research, not evidence of medical usefulness.

Source · Total Syntheses of Cannabicyclol, Clusiacyclol A and B, Iso-Eriobrucinol A and B, and Eriobrucinol

The 2025 finding

In cells, a 2025 study found that CBL could enhance serotonin-driven activation of the 5-HT1A receptor as a positive allosteric modulator. It did not investigate improvements in patients’ anxiety, sleep or mood.

The receptor’s name may sound familiar, making it tempting to fill in the rest of the story. But knowing one piece of a mechanism does not justify choosing a disease and declaring it treatable. A useful reading preserves the finding and stops before that leap.

Source · An Unexpected Activity of a Minor Cannabinoid: Cannabicyclol (CBL) Is a Potent Positive Allosteric Modulator of Serotonin 5-HT1A Receptor

What has been studied

No established clinical benefit

The receptor finding does not establish clinical improvement.

Source · An Unexpected Activity of a Minor Cannabinoid: Cannabicyclol (CBL) Is a Potent Positive Allosteric Modulator of Serotonin 5-HT1A Receptor

Risks and gaps

That cell assay does not establish safety in people.

Source · An Unexpected Activity of a Minor Cannabinoid: Cannabicyclol (CBL) Is a Potent Positive Allosteric Modulator of Serotonin 5-HT1A Receptor

Documented forms

Chemical-research materialThe documented synthesis enables compound research without validating a healthcare product.
Source · Total Syntheses of Cannabicyclol, Clusiacyclol A and B, Iso-Eriobrucinol A and B, and Eriobrucinol

A molecule and a product are different things. Read about flowers, resins, oils, creams, capsules and vaping.

Experiences

We have not included a verifiable individual account in this review. We do not fill that gap with commercial stories or invented experiences.

Conclusion

CBL deserves an up-to-date profile, with interest in the question and precision about the answer. “There is experimental activity” and “there is a demonstrated benefit” remain different claims.

Legal context

Read the Spain note and official sources. Absence from a cited list does not establish that a product is lawful.

Sources

  1. Total Syntheses of Cannabicyclol, Clusiacyclol A and B, Iso-Eriobrucinol A and B, and Eriobrucinol · Original research
  2. An Unexpected Activity of a Minor Cannabinoid: Cannabicyclol (CBL) Is a Potent Positive Allosteric Modulator of Serotonin 5-HT1A Receptor · Laboratory study

Source review: 2026-11-02. No external clinical review. Corrections: info@milnubes.com.